FBInvestor
Stocks / Theravance Biopharma Inc
Institutional Ownership

Theravance Biopharma Inc

CUSIP G8807B106COMTBPHQ1 2026

13D / 13G Filings
53
Schedule 13D/13G on record
Beneficial Filers
17
Distinct reporting persons
Largest Stake
19.5%
Max % of class reported
Institutional Holders
165
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

53 filings · latest Feb 17, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 17, 2026Newtyn Management, LLC13G/A8.5%4.30MSEC
2Apr 30, 2025Blackrock, Inc.13G/A6.5%3.24MSEC
3Feb 14, 2025Newtyn Management, LLC13G/A9.7%4.76MSEC
4Nov 14, 2024Madison Avenue Partners, LP13G/A19.4%9.51MSEC
5Nov 12, 2024Vanguard Group Inc13G/A4.2%2.05MSEC
6Nov 4, 2024Vanguard Group Inc13G/A4.2%2.05MSEC
7Nov 4, 2024Vanguard Group Inc13G/A4.2%2.05MSEC
8Sep 9, 2024Baupost Group LLC/Ma13G/ASEC
9Aug 16, 2024Newtyn Management, LLC13G8.4%4.10MSEC
10Aug 9, 2024Baupost Group LLC/Ma13G/A6.1%2.98MSEC

43 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Theravance Biopharma Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →